The impact of glucagon-like peptide-1 receptor agonist on the gastric residue in upper endoscopy
Authors' conclusion
Our results may have important clinical relevance for EGD preparation among GLP1-RA treated patients, either requiring a longer fasting time prior to EGD or holding the medication prior to EGD according to the half-life of the drug.
Study context
- Population
- All esophagogastroduodenoscopy (EGDs) conducted across seven gastroenterology departments
- Participants
- 120,879 EGDs
- Exposure
- GLP-1 RA use vs no GLP-1 RA
- GLP1-RAn = 1,671
- non-GLP1-RAn = 119,208reference
- Outcome
- Gastric residue on EGD (diagnosis of "poor preparation" or poor preparation described in endoscopist's report)
Methodological detailsmulticenter, seven gastroenterology departments
- Multicenter
- Seven gastroenterology departments
Main finding
As reported in the abstract
Gastric residue
P < 0.001
Observational data: associations, not effects.
Further findings
GLP1-RA (DM, n=1141) vs non-GLP1-RA (DM, n=10,152)
Gastric residue, DM subgroup
P < 0.001
GLP1-RA (non-DM, n=503) vs non-GLP1-RA (non-DM, n=109,056)
Gastric residue, non-DM subgroup
P < 0.001
Multivariate analysis
- DM and GLP-1 RA both independent risk factors for excess gastric residue
Original publication
The impact of glucagon-like peptide-1 receptor agonist on the gastric residue in upper endoscopy. Diabetes Res Clin Pract. Published 19 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →